Clinical trials: Connective Tissue Diseases
Urticaria
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
This open-label study is being conducted to determine the effect of DL treatment for CIU on symptom and disease severity, quality of life, daytime functioning, and quality of sleep.
- Trial name
- NCT00795522
- Testing
- Desloratadine
- Volunteers
- 51 people
- Sponsor
- Organon and Co
System; Lupus Erythematosus, Lupus Erythematosus
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
This study is investigating the development of a diagnostic test intended to predict flares in patients with Systemic Lupus Erythematosus.
- Conditions
- System; Lupus Erythematosus, Lupus Erythematosus, SLE, Lupus Flare
- Trial name
- TOTAL FEEDBACK (NCT04018222)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Progentec Diagnostics, Inc.
Diabetic Foot Ulcer
Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers
This study randomly assigns patients with diabetic foot ulcers to receive standard therapy (surgical debridement, saline-moistened gauze and offloading) alone or standard therapy plus Dermagraft(R).
- Trial name
- NCT01181453
- Testing
- Dermagraft, Comparator
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- Organogenesis
Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis…
- Trial name
- RA-BRANCH (NCT04086745)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 119 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with…
- Trial name
- KATE2 (NCT02924883)
- Testing
- Atezolizumab, Trastuzumab emtansine
- Where
- 68 sites in United States, Australia and 7 more
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Breast Neoplasms
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body…
- Trial name
- NCT06966453
- Testing
- Disitamab vedotin
- Where
- 145 sites in United States, Australia and 7 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
Diffuse Cutaneous Systemic Sclerosis
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
This is a multicenter, open-label study to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive Diffuse Cutaneous Systemic Sclerosis (dcSSc) at risk for organ…
- Trial name
- FREEDOM-3 (NCT05098145)
- Testing
- FCR001
- Where
- United States
- Sponsor
- Talaris Therapeutics Inc.
Dermatitis
Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis
A study of subjects with a known nickel allergy comparing Tacrolimus to placebo, both associated with nickel patches to determine the safety and efficacy of treating Chronic Allergic Contact Dermatitis with Tacrolimus Ointment
- Trial name
- NCT00667056
- Testing
- tacrolimus ointment
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Inc
Mild to Moderate Psoriasis
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.
- Trial name
- NCT03222622
- Testing
- Icotinib hydrochloride cream
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Urticaria
Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria
· To evaluate the efficacy of rupatadine 10 and 20 mg for the treatment of CIU symptoms over four-week treatment period in comparison with placebo.
- Trial name
- NCT00199251
- Testing
- RUPATADINE
- Volunteers
- 300 people
- Sponsor
- J. Uriach and Company
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Hidradenitis Suppurativa
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT02904902
- Testing
- adalimumab
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- AbbVie
Diabetes, Foot Ulcer
Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer
It is estimated that 300 million people worldwide will have diabetes by the year 2025. About 12 percent of those with diabetes will have had a foot ulcer, which is a major source of morbidity, concern, and cost.
- Trial name
- DERMAGEN® (NCT00521937)
- Testing
- Dermagen®
- Where
- 7 sites in France
- Volunteers
- 388 people
- Sponsor
- Laboratoires Genévrier
Cancer, Cancer (Solid Tumors)
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT07317505
- Testing
- JMT108
- Where
- 3 sites in United States
- Volunteers
- 270 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Acne Vulgaris
Efficacy and Tolerability Evaluation of a Novel Dermo-cosmetic Product for Mild-to-moderate Acne
The goal of this non-interventional, observational study is to evaluate the real-world efficacy and tolerance of a novel dermocosmetic cream containing 15% Azelaic acid and a complex of active ingredients (α-AZ cream) in patients…
- Trial name
- NCT07759505
- Where
- Romania
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- ISISPHARMA
Breast Cancer
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay
The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and…
- Trial name
- NCT01974856
- Where
- 2 sites in Germany
- Volunteers
- 201 people
- Sponsor
- NanoString Technologies, Inc.
Port-Wine Stain
Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in…
- Trial name
- NCT03181984
- Testing
- Hemoporfin
- Where
- 7 sites in China
- Volunteers
- 501 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called…
- Trial name
- NCT05650333
- Testing
- Ritlecitinib 20 mg
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Malignant Melanoma, Melanoma
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body.
- Conditions
- Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
- Trial name
- NCT06799533
- Testing
- PF-08046031
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
A special investigation (post marketing observational study [PMOS]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
- Trial name
- NCT02414633
- Volunteers
- 148 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.